Methods and compositions for inhibiting angiogenesis
The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease.
1. A composition comprising an isolated peptide attached to a non-amino acid chemical moiety, wherein said peptide:
i) consists of the amino acid sequence in SEQ ID NO:2;
ii) consists of the amino acid sequence in SEQ ID NO: 11;
iii) consists of the amino acid sequence in SEQ ID NO: 61; or
iv) consists of the amino acid sequence in SEQ ID NO: 102; and
wherein said non-amino acid chemical moiety is a fluorescent compound or a targeting carrier.
2. The composition of claim 1 , wherein said peptide exhibits anti-angiogenic activity.
3. The composition of claim 1 , wherein said peptide consists of the amino acid sequence shown in SEQ ID NO:102.
4. The composition of claim 1 , further comprising an anti-cancer agent different from said peptide.
5. The composition of claim 4 , wherein said anti-cancer agent comprises rapamycin.
6. The composition of claim 1 , further comprising a physiological tolerable buffer.
7. The composition of claim 1 , further comprising an anti-angiogenic agent different from said peptide.
8. The composition of claim 1 , wherein said composition is a pharmaceutical composition.
9. A method of inhibiting angiogenesis, comprising: contacting a tissue exhibiting angiogenesis with a composition comprising an isolated peptide under conditions such that angiogenesis is decreased in said tissue, wherein said peptide consists of an amino acid sequence selected from the group consisting of: SEQ ID NO:2 and a fragment of SEQ ID NO:2 exhibiting anti-angiogenic activity.
10. The method of claim 9 , wherein said fragment of SEQ ID NO:2 consists of SEQ ID NO:11.
11. A composition comprising an isolated peptide covalently linked to a targeting carrier, a fluorescent compound, and/or active pharmaceutical, wherein said peptide:
i) consists of the amino acid sequence in SEQ ID NO:2;
ii) consists of the amino acid sequence in SEQ ID NO:11;
iii) consists of the amino acid sequence in SEQ ID NO:61; or
iv) consists of the amino acid sequence in SEQ ID NO:102.
12. The method of claim 9 , wherein said fragment of SEQ ID NO:2 consists of SEQ ID NO:102.
13. The method of claim 9 , wherein said composition further comprises a non-amino acid chemical moiety, wherein said non-amino acid chemical moiety is attached to, or associated with, said peptide.
14. The method of claim 9 , wherein said composition further comprises a physiological tolerable buffer.
15. The method of claim 9 , wherein said composition further comprises an anti-angiogenic agent different from said peptide.
16. The method of claim 9 , further comprising the step of administering a second agent to said tissue.
17. The method of claim 9 , wherein said tissue is cancerous tissue.
18. The method of claim 9 , wherein said tissue is in a subject.